Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Floquet

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2017
Networking for ovarian rare tumors: a significant breakthrough improving disease managementN Chiannilkulchai, P Pautier, C Genestie, et al.
British Journal of Cancer|January 11, 2017
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO groupP-E Heudel, M Fabbro, C Roemer-Becuwe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma GroupP Pautier, A Floquet, L Gladieff, et al.
Gynecologic Oncology|September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancerI Vergote, A du Bois, A Floquet, et al.
Gynecologic Oncology|March 6, 2020
The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group StudyC Lenck, N Chopin, S Gouy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2019
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I studyF Joly, D Ahmed-Lecheheb, E Kalbacher, et al.
Gynecologic Oncology|July 7, 2020
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG networkF Derquin, A Floquet, A C Hardy-Bessard, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2017
Networking for ovarian rare tumors: a significant breakthrough improving disease managementN Chiannilkulchai, P Pautier, C Genestie, et al.
British Journal of Cancer|January 11, 2017
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO groupP-E Heudel, M Fabbro, C Roemer-Becuwe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma GroupP Pautier, A Floquet, L Gladieff, et al.
Gynecologic Oncology|September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancerI Vergote, A du Bois, A Floquet, et al.
Gynecologic Oncology|March 6, 2020
The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group StudyC Lenck, N Chopin, S Gouy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2019
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I studyF Joly, D Ahmed-Lecheheb, E Kalbacher, et al.
Gynecologic Oncology|July 7, 2020
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG networkF Derquin, A Floquet, A C Hardy-Bessard, et al.
Pageof 5